Dear EURETINA Members, A very warm welcome to the July 24th, 2024 edition of EURETINA’s web-based digital periodical, “EURETINA Brief”. EURETINA are delighted to continue… Read More »July 24th, 2024 “EURETINA-Brief”© Issue No. 296
Researchers at the School of Pharmacy, University of Eastern Finland, and the Gavin Herbert Eye Institute-Center for Translational Vision Research, Department of Ophthalmology, University of… Read More »Re-purposed drugs for retinitis pigmentosa may address mutation-independent approach for retinal degenerations.
Researchers at UCL Institute of Ophthalmology, University College London, and Moorfields Eye Hospital, have reported a detailed natural history, retinal imaging dataset and clinical features… Read More »A first in-depth retrospective longitudinal study of Usher syndrome on USH1D, providing key natural history, image data and clinical features.
A private biotech company, Beacon Therapeutics, based in London, UK (and Florida and Cambridge, USA), has received an investment of $170M from several funding partners,… Read More »Beacon Therapeutics has announced an investment of $170M for the development of ophthalmic gene therapies.
According to the Royal College of Ophthalmologists, the term of “low vision” is not defined in UK legislation however, the UK Low Vision Services Consensus… Read More »Book Review of Low Vision-Principles and Management, 1st edition (Elsevier); by Christine Dickinson, Ana Hernandez Trillo and Michael Crossland
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), have announced the reintroduction of “Susvimo” (ranibizumab injection) 100 mg/mL for intravitreal use… Read More »Genentech (Roche Group) announce that FDA has approved the introduction of Susimvo (ranibizumab injection, ocular implant) for wet age-related macular degeneration.
Researchers at the Center for Ophthalmic Bioinformatics Research at the Cole Eye Institute, Cleveland, Ohio, have reported that the prevalence of diabetic retinopathy (DR) changed… Read More »Early warning signs of diabetic retinopathy (DR) in clinics shows exponentially increases in prevalence on type 1 DR and type 2 DR.
Researchers based at the Nuffield Department of Clinical Neurosciences, The John Radcliffe Hospital, University of Oxford, have reported a new study on the mechanism of… Read More »AAV treatment or surgical issues on chorioretinal atrophy? Researchers report on a study on potential adverse events in a gene therapy treatment.
Dear EURETINA Members, A very warm welcome to the July 10th, 2024 edition of EURETINA’s web-based digital periodical, “EURETINA Brief”. EURETINA are delighted to continue… Read More »July 10th. 2024 “EURETINA-Brief”© Issue No. 295
Nanoscope Therapeutics Inc., a company based in Bedford, Texas, has provided an update following recent regulatory discussions with the U.S. Food and Drug Administration (“FDA”)… Read More »Nanoscope Therapeutics Inc., provides a commercial update on MCO-010 treatment of retinitis pigmentosa (RP) using optogenetic therapy.
